Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more
Durect Corporation (DRRX) - Net Assets
Latest net assets as of June 2025: $3.94 Million USD
Based on the latest financial reports, Durect Corporation (DRRX) has net assets worth $3.94 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.48 Million) and total liabilities ($8.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.94 Million |
| % of Total Assets | 31.54% |
| Annual Growth Rate | -3.23% |
| 5-Year Change | -77.24% |
| 10-Year Change | -38.65% |
| Growth Volatility | 211.02 |
Durect Corporation - Net Assets Trend (1999–2024)
This chart illustrates how Durect Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Durect Corporation (1999–2024)
The table below shows the annual net assets of Durect Corporation from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.13 Million | -38.23% |
| 2023-12-31 | $14.78 Million | -40.83% |
| 2022-12-31 | $24.98 Million | -56.76% |
| 2021-12-31 | $57.78 Million | +44.04% |
| 2020-12-31 | $40.12 Million | +75.48% |
| 2019-12-31 | $22.86 Million | +14.30% |
| 2018-12-31 | $20.00 Million | -6.92% |
| 2017-12-31 | $21.49 Million | +157.71% |
| 2016-12-31 | $8.34 Million | -43.98% |
| 2015-12-31 | $14.88 Million | -19.62% |
| 2014-12-31 | $18.52 Million | -39.73% |
| 2013-12-31 | $30.72 Million | -15.44% |
| 2012-12-31 | $36.33 Million | +944.90% |
| 2011-12-31 | $3.48 Million | -76.00% |
| 2010-12-31 | $14.49 Million | -47.16% |
| 2009-12-31 | $27.42 Million | -24.72% |
| 2008-12-31 | $36.42 Million | +5.32% |
| 2007-12-31 | $34.58 Million | -6.62% |
| 2006-12-31 | $37.03 Million | -14.58% |
| 2005-12-31 | $43.35 Million | +135.74% |
| 2004-12-31 | $18.39 Million | -59.24% |
| 2003-12-31 | $45.12 Million | -31.83% |
| 2002-12-31 | $66.18 Million | -31.80% |
| 2001-12-31 | $97.05 Million | -15.80% |
| 2000-12-31 | $115.25 Million | +456.03% |
| 1999-12-31 | $20.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Durect Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58669800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $23.00K | 0.25% |
| Other Comprehensive Income | $-1.00K | -0.01% |
| Other Components | $606.44 Million | 6641.54% |
| Total Equity | $9.13 Million | 100.00% |
Durect Corporation Competitors by Market Cap
The table below lists competitors of Durect Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daesung Energy
KO:117580
|
$50.56 Million |
|
Village Bank and Trust Financial
NASDAQ:VBFC
|
$50.56 Million |
|
Falcon Machine Tools Co Ltd
TWO:4513
|
$50.62 Million |
|
Weblink International Inc
TW:6776
|
$50.63 Million |
|
YASHO INDUSTRIES ORD (BSE)
NSE:YASHO
|
$50.54 Million |
|
Nightingale Health Oyj B
HE:HEALTH
|
$50.54 Million |
|
ETHZilla Corporation
NASDAQ:ETHZ
|
$50.52 Million |
|
NANOFORM FINLAND OYJ
F:4YL
|
$50.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Durect Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,783,000 to 9,131,000, a change of -5,652,000 (-38.2%).
- Net loss of 8,324,000 reduced equity.
- New share issuances of 648,000 increased equity.
- Other comprehensive income increased equity by 13,000.
- Other factors increased equity by 2,011,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.32 Million | -91.16% |
| Share Issuances | $648.00K | +7.1% |
| Other Comprehensive Income | $13.00K | +0.14% |
| Other Changes | $2.01 Million | +22.02% |
| Total Change | $- | -38.23% |
Book Value vs Market Value Analysis
This analysis compares Durect Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.30x to 6.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $6.30 | $1.91 | x |
| 2000-12-31 | $34.87 | $1.91 | x |
| 2001-12-31 | $20.91 | $1.91 | x |
| 2002-12-31 | $13.70 | $1.91 | x |
| 2003-12-31 | $8.93 | $1.91 | x |
| 2004-12-31 | $3.57 | $1.91 | x |
| 2005-12-31 | $8.07 | $1.91 | x |
| 2006-12-31 | $5.61 | $1.91 | x |
| 2007-12-31 | $4.91 | $1.91 | x |
| 2008-12-31 | $4.65 | $1.91 | x |
| 2009-12-31 | $3.29 | $1.91 | x |
| 2010-12-31 | $1.67 | $1.91 | x |
| 2011-12-31 | $0.40 | $1.91 | x |
| 2012-12-31 | $4.10 | $1.91 | x |
| 2013-12-31 | $2.98 | $1.91 | x |
| 2014-12-31 | $1.66 | $1.91 | x |
| 2015-12-31 | $1.26 | $1.91 | x |
| 2016-12-31 | $0.63 | $1.91 | x |
| 2017-12-31 | $1.48 | $1.91 | x |
| 2018-12-31 | $1.25 | $1.91 | x |
| 2019-12-31 | $1.28 | $1.91 | x |
| 2020-12-31 | $2.01 | $1.91 | x |
| 2021-12-31 | $2.57 | $1.91 | x |
| 2022-12-31 | $1.10 | $1.91 | x |
| 2023-12-31 | $0.56 | $1.91 | x |
| 2024-12-31 | $0.30 | $1.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Durect Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -91.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -409.85%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 2.01x
- Recent ROE (-91.16%) is above the historical average (-113.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -42.01% | -10125.58% | 0.00x | 1.08x | $-10.78 Million |
| 2000 | -17.22% | -629.19% | 0.03x | 1.05x | $-31.38 Million |
| 2001 | -46.29% | -688.66% | 0.06x | 1.08x | $-54.63 Million |
| 2002 | -56.17% | -517.37% | 0.10x | 1.10x | $-43.79 Million |
| 2003 | -50.31% | -191.79% | 0.11x | 2.49x | $-27.21 Million |
| 2004 | -150.28% | -199.50% | 0.16x | 4.65x | $-29.48 Million |
| 2005 | -41.82% | -63.45% | 0.24x | 2.71x | $-22.46 Million |
| 2006 | -90.00% | -152.22% | 0.21x | 2.77x | $-37.03 Million |
| 2007 | -70.38% | -79.34% | 0.37x | 2.43x | $-27.80 Million |
| 2008 | -123.70% | -173.56% | 0.35x | 2.06x | $-48.69 Million |
| 2009 | -112.03% | -126.44% | 0.42x | 2.12x | $-33.46 Million |
| 2010 | -158.06% | -72.48% | 0.47x | 4.66x | $-24.35 Million |
| 2011 | -539.69% | -56.04% | 0.68x | 14.15x | $-19.11 Million |
| 2012 | 44.59% | 30.53% | 1.16x | 1.26x | $12.57 Million |
| 2013 | -69.83% | -139.97% | 0.38x | 1.33x | $-24.52 Million |
| 2014 | -119.42% | -113.96% | 0.39x | 2.71x | $-23.96 Million |
| 2015 | -152.27% | -118.51% | 0.41x | 3.14x | $-24.15 Million |
| 2016 | -413.88% | -246.05% | 0.35x | 4.86x | $-35.34 Million |
| 2017 | -17.20% | -7.51% | 0.93x | 2.47x | $-5.84 Million |
| 2018 | -126.61% | -136.40% | 0.37x | 2.50x | $-27.32 Million |
| 2019 | -90.02% | -69.60% | 0.34x | 3.76x | $-22.86 Million |
| 2020 | -33.47% | -44.59% | 0.40x | 1.89x | $-17.44 Million |
| 2021 | -62.76% | -259.46% | 0.15x | 1.59x | $-42.04 Million |
| 2022 | -141.42% | -183.23% | 0.32x | 2.41x | $-37.83 Million |
| 2023 | -186.86% | -323.16% | 0.19x | 3.06x | $-29.10 Million |
| 2024 | -91.16% | -409.85% | 0.11x | 2.01x | $-9.24 Million |
Industry Comparison
This section compares Durect Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Durect Corporation (DRRX) | $3.94 Million | -42.01% | 2.17x | $50.56 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |